<DOC>
	<DOCNO>NCT00465283</DOCNO>
	<brief_summary>This double blind randomize investigation donepezil patient suffer schizophrenia , undergo ECT . Patients randomize receive either donezepil plasebo , order gauge whether donezepil protective effect memory disfunction , patient treat ECT . Several parameter invistigated baseline : general psychopathological measure , memory function scale , side effect scale . The measurement take throughout trial one month end ECT .</brief_summary>
	<brief_title>Donepezil Double Blind Trial ECT Memory Disfunction</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Schizophrenia , Schizoaffective disorder , schizophreniform disorder patient meet criterion diagnose DSMIV criterion evaluate Structured Clinical Interview DSMIV ( SCID ) History serious neurological disorder include neurodegenerative deseases , mental retardation , substance and/or alcohol dependence . Pregnant woman Patients recieved ECT within 6 month Patients whith contraindication Donepezil treatment . Patients Lithium treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Donepezil , ECT , Memory Disfunction</keyword>
</DOC>